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Questions for Panel I
DR. SEASHORE: Many issues have been raised that merit further exploration, and the
panel is ready to open the discussion to the group.
QUESTION: How does Dr. Naylorobtain informed consent in the kind ofscreening his
laboratory is doing?
DR. NAYLOR: The program in Pittsburgh is a routine program that is offered on a
hospital-to-hospital basis; the hospitals that joined offer it to all of their babies,
generally as a standing order in the newborn nursery. Parents are given patient
educational brochures before they enter the hospital, at the time of delivery, and
they have an option to choose not to have the screening done as part of the
procedure. Our program is set up exactly as the state of Pennsylvania is for their
PKU and hypothyroidism, with the informed ability to decline to participate, rather
than any signed consent form.
QUESTION: How are these new technologies being used in the field of behavior
genetics?
DR. NAYLOR: I assume you are talking about manicdepression, schizophrenia. I don't
really see it as part ofnewborn screening.
DR. SEASHORE: What criteria can be used to decide that a test is ready to leave the
research laboratory and be used in a diagnostic way? How has the Pittsburgh group
made those kinds ofdecisions?
DR. NAYLOR: The major criterion that I used was, with the exception ofpyroglutamic
aciduria, all ofthe other tests in our program are in routine use at some place in the
United States and throughout the world. The molecularwork has been an add-on as
part ofthe confirmatory aspect ofit.
QUESTION: What is the cost ofthis kind oftesting?
DR. NAYLOR: The single $15 charge includes all the repeat testing, whether that's a
repeat CPK or repeat trypsin or whatever. We do the multiplex PCR or the three
base pair deletion at no additional charge to the family as part of the confirmatory
procedure on the patient. We then do the Southern blot analysis or additional PCR
on immediate family members. We do provide genetic counseling if they wish it. If
testing does go beyond the parents and the patient to other extended family
members, then that is something that theywould be charged for.
QUESTION: What is usually done with the screening sample filter papers? How long
are those samples useful to us?
DR. LEVY: In Massachusetts, the newborn blood specimen is saved for about three
years. Until about 10 or 12 years ago, Massachusetts never threw a blood specimen
away. From 1962 until about 1978, a period of 16years, all newborn blood specimens
were saved in some place at the Massachusetts State Laboratory. It was overrunning
the laboratory. The reason that we thought we should never discard a specimen was
because we thought it might have some greatvalue in two respects:
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To allow us to go back if a patient were missed by newborn screening and
determine how the mistake occurred by simply going back to the blood
specimen and testing it again; phenylalanine is very stable, like most amino
acids, and it remains in filter paper specimens for many, many years, pretty
much in the same concentration that it was there in the beginning.
Precisely for the reason that Ed gave that they used the specimen in England,
and that is to go back to a child who might have died or might no longer be
accessible and test that specimen for some particular scientific or clinical
reason having to do with the biology of a disease or the science of a problem.
Most other states, I think, keep specimens for between two and fiveyears.
DR. MCCABE: I think California keeps them indefinitely.
COMMENT: California keeps them for at least tenyears at -200C.
COMMENT: New York discards them after six months, mainly because of space
requirements.
COMMENT: Connecticut now discards them after six months.
DR. SEASHORE: It's an interesting question and perhaps ought to be the subject of a
panel sometime tomake a policystatement, particularly the issue ofachild no longer
being accessible and such powerful technologybecoming available.
DR. MCCABE: But that would probably get into an issue that Lori Andrews would
address about who has access to those.
DR. SEASHORE: Of course, just because something is stored doesn't mean that
automatically anyone who wants it can have access to it. We store money in banks,
but that doesn't mean that anyone can walk in and take it.
COMMENT: What about HIV contamination?
DR. SEASHORE: Is HIV recoverable as an infectious agent from dried blood on filter
paper?
COMMENT: Not according to the CDC. I think it's 24 hours or something. The
problem is that there was a conflict in recommendations. The recommendation for
newborn screening is to let it dry and then sent it in a paperenvelope. Then the CDC
came up with treating it because of the possibility of HIV, putting it into a plastic
envelope where it wouldn't dry, and there were some serious problems with the
stability of some of the analytes when that type of sample was handled that way. I
think that's been resolved now. There was a period oftime when that procedure was
a problem.
DR. LEVY: In Boston we have them keep the filter paper out for 20 minutes and when
they're completely drywe put them inplasticbags-but they are allowed todry about
20 minutes first.
QUESTION: What are the criteria for initiating screening? What are some of the
criteria used to discontinue the screening?
DR. LEVY: It's spelled m-o-n-e-y. Literally so. For instance, you may be referring to
biotinidase screening, which I think is averyvalid addition to newborn screening. We
did have a grant from the New England Regional Genetics Group to do a pilot study
of biotinidase screening, and it was, I think, very successful. Out of 100,000
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specimens, we picked up three cases in two families and the children are doing well.
But we didn't have any money to pick up after the grant ran out; the money ran out,
so that was the end ofthat. We have been piloting otherscreening such as congenital
adrenal hyperplasia and sickle-cell anemia, which, in addition to biotinidase defi-
ciency, are very valid additions to newborn screening. Whatever we have discontin-
ued has been due to lack ofmoney.
QUESTION: What decision-making approaches are recommended to set these policies
Are there any accepted decision-making rules that the genetics community recom-
mends to a policy maker?
DR. LEVY: I don't know that there are very many state or regional newborn screening
programs that have well-thought-out, well-constructed, policy decision-making orga-
nizations in place that dictate the course of newborn screening. I can think of one
possible exception, Maryland. I think that in most screening programs the decisions
as to what to add to newborn screening or what to subtract from newborn screening
are made on anadhoc basis.
DR. MCCABE: This is basically a process of accretion in the states-there are usually
historical reasons; sometimes it's special interest groups, but largely historical.
CORN, the Council of Regional Networks for genetic services, has a newborn
screening subcommittee and is trying to develop minimal guidelines. Historically, or
by standard of care, all states screen for PKU and congenital hypothyroidism, and
there is the NIH consensus statement recommending universal screening for sickle-
cell disease. One could take that as the minimal battery. Otherwise, they're usually
adhoc individual decisions.
DR. NAYLOR: In the case of the state of Pennsylvania, political concerns are
important. The interest in sickle-cell screening which is being contemplated is
coming from the Philadelphia area, from the black legislators. The state is also
looking atthepossibilityofaddingmaple syrup urine disease inplace ofgalactosemia
or biotinidase deficiency, although the incidence of MSUD is about one in a quarter
million babies. The reason is that Pennsylvania has averyhigh incidence ofMSUD in
the Mennonite population. The incidence in that population is about 1 in 750. That
changes the State of Pennsylvania's frequency from 1 in one-quarter million to 1 in
70,000 newborns, almost 80 percent ofwhich are in the Mennonites.
DR. SEASHORE: That raises the question of targeted or directed screening versus
universal screening andwhetherthere is a role for such decisions asyou talked about
in Pennsylvania. In a particular areawhere the incidence ofa disease is high, canyou
make an argument for targeted screening, or is that too difficult politically and
ethically?
DR. NAYLOR: I think it's hard to segregate out a single population. The Mennonite
population has spread fairly far and wide from the original location in Lancaster
County. Maryland's high incidence ofmaple syrup urine disease is largely among the
Mennonites who have moved there. The early screening programs for congenital
adrenal hyperplasia in the State of Washington targeted the Alaska population
because ofthe high incidence ofthat condition in the Yupik Eskimos. There is some
justification to targeted screening, if there are subpopulations within a state with
especially high or low incidence ofa disorder.
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